Targeted Oncology

Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

As a hybrid journal, Targeted Oncology does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Targeted Oncology offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Contact: For more information about the journal, including pre-submission enquiries, please contact Martin Chopra at martin.chopra@springer.com